Maarten van der Doelen

Chapter 8

50. Badrising SK, Louhanepessy RD, van der Noort V, Coenen J, Hamberg P, Beeker A, et al. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. Int J Cancer. 2020;147(4):1143-51. 51. Bauckneht M, Rebuzzi SE, Signori A, Frantellizzi V, Murianni V, Lodi Rizzini E, et al. The prognostic power of inflammatory indices and clinical factors in metastatic castration resistant prostate cancer patients treated with radium-223 (BIO-Ra study). Eur J Nucl Med Mol Imaging. 2022;49(3):1063-74. 52. Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016;43(1):8-20. 53. Frantellizzi V, Monari F, Mascia M, Costa R, Rubini G, Spanu A, et al. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with (223)Radium-dichloride: a national multicenter study. Ann Nucl Med. 2020;34(10):772-80. 54. Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090-7. 55. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306-16. 56. Fosbol MO, Petersen PM, Kjaer A, Mortensen J. (223)Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity. J Nucl Med. 2018;59(4):596 602. 57. Anand A, Tragardh E, Edenbrandt L, Beckman L, Svensson JH, Thellenberg C, et al. Assessing Radiographic Response to (223)Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients. J Nucl Med. 2020;61(5):671-5. 58. Frantellizzi V, Pani A, Ippoliti MD, Farcomeni A, Aloise I, Colosi M, et al. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment. Radiol Oncol. 2019;54(1):40-7. 59. RoqueV, JessopM, Pereira L, Gape P, Dizdarevic S, Sousa E, et al. Bone scan index asmetastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response. Nucl Med Commun. 2019;40(6):588-96. 60. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015;56(8):1177-84. 61. Filippi L, Spinelli GP, Chiaravalloti A, Schillaci O, Equitani F, Bagni O. Prognostic Value of (18) F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223. Biomedicines. 2020;8(12):555.

222